Provided by Tiger Trade Technology Pte. Ltd.

Larimar Therapeutics, Inc.

4.05
-0.1300-3.11%
Volume:945.55K
Turnover:3.84M
Market Cap:421.20M
PE:-2.10
High:4.23
Open:4.23
Low:3.93
Close:4.18
52wk High:6.42
52wk Low:2.72
Shares:104.00M
Float Shares:57.54M
Volume Ratio:0.98
T/O Rate:1.64%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.9258
EPS(LYR):-2.2711
ROE:-139.63%
ROA:-70.96%
PB:3.31
PE(LYR):-1.78

Loading ...

U.S. RESEARCH ROUNDUP- Agilent Technologies, Fedex, Synopsys

Reuters
·
May 27

Larimar Therapeutics Inc : JP Morgan Initiates Coverage With Overweight Rating; Price Target $9

THOMSON REUTERS
·
May 27

Larimar Therapeutics shareholders approve increase in authorized common shares to 215 million

Reuters
·
May 20

Exploring US High Growth Tech Stocks This May 2026

Simply Wall St.
·
May 15

Larimar Therapeutics Q1 net loss widens slightly R&D expenses fall

Reuters
·
May 14

BRIEF-Larimar Therapeutics Q1 Net Income USD -29.613 Million

Reuters
·
May 14

Larimar Therapeutics Q1 EPS USD -0.31

THOMSON REUTERS
·
May 14

Larimar Therapeutics Reports First Quarter 2026 Financial and Business Update

THOMSON REUTERS
·
May 14

Top News Today: Stocks Rise, Oil Falls, as War Restart Fears Subside

Dow Jones
·
May 06

Larimar study backs skin frataxin as surrogate endpoint for nomlabofusp trials

Reuters
·
May 01

Larimar Therapeutics Inc expected to post a loss of 54 cents a share - Earnings Preview

Reuters
·
Apr 24

Larimar Therapeutics announces annual stockholder meeting

Reuters
·
Apr 11

Nomlabofusp’s Manageable Risk, Strong Efficacy Signals, and Significant FA Market Upside Underpin Buy Rating on LRMR

TIPRANKS
·
Apr 01

Larimar Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
Mar 23

Larimar Therapeutics Inc expected to post a loss of 52 cents a share - Earnings Preview

Reuters
·
Mar 20

Citi Reaffirms Their Buy Rating on Larimar Therapeutics (LRMR)

TIPRANKS
·
Mar 20

Larimar Therapeutics Q4 net loss rises more than doubled to USD 62.5 million as R&D expenses jump more than doubled to USD 59.4 million

Reuters
·
Mar 19

BRIEF-Larimar Therapeutics Q4 Net Income USD -62.498 Million

Reuters
·
Mar 19

Larimar Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results

THOMSON REUTERS
·
Mar 19

Larimar Therapeutics Inc - Bla Submission Planned for June 2026; U.S. Launch Targeted First-Half 2027

THOMSON REUTERS
·
Mar 19